drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Chimeric anti-CD20 monoclonal antibody (IV; 1000 mg ×2, 2 weeks apart) that depletes CD20+ B cells via complement- and antibody-dependent cytotoxicity and apoptosis to reduce pathogenic autoantibodies and immune-mediated inflammation in SLE-PAH. Brand used: Hanlikang.
nci_thesaurus_concept_id
C1702
nci_thesaurus_preferred_term
Rituximab
nci_thesaurus_definition
A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)
drug_mesh_term
Rituximab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric anti-CD20 monoclonal antibody that binds CD20 on pre‑B and mature B cells and induces complement‑dependent cytotoxicity, antibody‑dependent cellular cytotoxicity, and apoptosis, leading to depletion of CD20+ B cells and reduction of autoantibody-driven inflammation.
drug_name
Rituximab
nct_id_drug_ref
NCT05828147